BioAtla Inc. (BCAB)
NASDAQ: BCAB
· Real-Time Price · USD
0.61
-0.02 (-3.16%)
At close: Sep 26, 2025, 10:59 AM
-3.16% (1D)
| Bid | 0.43 |
| Market Cap | 36.1M |
| Revenue (ttm) | 11M |
| Net Income (ttm) | -59.52M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -0.51 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 0.62 |
| Volume | 89,564 |
| Avg. Volume (20D) | 786,580 |
| Open | 0.62 |
| Previous Close | 0.63 |
| Day's Range | 0.61 - 0.63 |
| 52-Week Range | 0.24 - 2.52 |
| Beta | 0.91 |
| Ex-Dividend Date | n/a |
About BCAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+13.92%
BioAtla shares are trading higher after the compan...
Unlock content with
Pro Subscription
3 months ago
+24.69%
BioAlta shares are trading higher after the company provided updates from its Phase 2 trial of Ozuriftamab Vedotin.
